Home/Jazz Pharmaceuticals/Philip L. Johnson
PL

Philip L. Johnson

Executive Vice President and Chief Financial Officer

Jazz Pharmaceuticals

Jazz Pharmaceuticals Pipeline

DrugIndicationPhase
VyxeosAcute Myeloid LeukemiaCommercial
DefitelioHepatic Veno-Occlusive DiseaseCommercial
SunosiNarcolepsy and Idiopathic HypersomniaCommercial
EpidiolexRare EpilepsiesCommercial
Oncology Pipeline ProgramsVarious Cancer TypesPre-clinical/Clinical